Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01833897 · ClinicalTrials.gov registry record · Phase 4
NMDA Antagonists in Bipolar Depression
A Phase 4 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 8
- Enrollment target
NCT01833897: Completed Phase 4 study, sponsored by New York State Psychiatric Institute.
NCT01833897 is a Phase 4 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 8 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01833897, a Phase 4 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cycloserine will serve as an effective therapy following ketamine treatment.
Primary Outcome
Depression rating scale: Range 0-53, higher scores indicate worse depression. 0-7 = Normal 8-13 = Mild Depression 14-18 = Moderate Depression 19-22 = Severe Depression ≥ 23 = Very Severe Depression
Interventions
- DRUG Ketamine
- DRUG Standard of Care
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-03 |
| Est. Completion | 2016-03 |
| Phase | Phase 4 |
What the finished NCT01833897 record still lists
NCT01833897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Ketamine is the first listed.
NCT01833897 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01833897 about?
NCT01833897 is a clinical study titled "NMDA Antagonists in Bipolar Depression". The purpose of this study is to test whether ketamine and D-cycloserine can be safely and effectively used for the treatment of depression. The investigators hypothesize that ketamine will serve as a rapid acting and safe antidepressant in patients with bipolar depression, and furthermore, that D-cy...
What is the current status of trial NCT01833897?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2013-03. Estimated completion is 2016-03.
What interventions are being tested in trial NCT01833897?
The interventions under investigation include: Ketamine (DRUG), Standard of Care (DRUG), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT01833897?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01833897's enrollment target sits among peer trials
8 1972nd of 2000 higher than 20 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia